Lowell owned 5% of CA preroll market with legacy products.
Launched 35’s on 9/29 in 16 stores - in 4 weeks went from 5% baseline to 13% for prerolls (up to 19% in some stores).
Minimal cannibilization on legacy side, early repeat buying data is solid.
Launch pace limited by product availability but by end of Oct expect to be in 100 stores.
Capacity expansion will continue to ramp through mid 2023.
Also planning to expand 35’s via licensing outside CA with boots on ground in 23 (is New York wishful thinking?).
Extraordinary value proposition for target consumer:
35’s pricing - below 88% of all flower in CA and priced Below 98% of all prerolls in CA.
Going after the heavy cannabis user highly price/quality sensitive.
Growth vector going forward: Increase output capacity and drive efficiency.
Win on quality, convenience and price.
Two questions jump out:
1) does product have staying power in a crowded and competitive market once “novelty” of 35s wears off?
2) if answer to #1 is yes then how do well capitalized competitors respond to losing significant share?
Exciting times to be a Lowell shareholder!

Liked By
Spread the love. Be the first to like this post!
Recent LOWLF News
- Annual Report (10-k) • Edgar (US Regulatory) • 03/31/2023 10:10:35 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/30/2023 09:01:59 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/16/2023 05:37:12 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/23/2023 08:53:07 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 01/13/2023 06:40:12 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 12/08/2022 02:22:26 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 12/08/2022 02:21:07 PM
- Initial Statement of Beneficial Ownership (3) • Edgar (US Regulatory) • 12/07/2022 06:09:20 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 12/02/2022 01:06:06 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/21/2022 09:45:50 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 11/14/2022 09:58:02 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/14/2022 04:24:48 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/09/2022 10:01:41 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/27/2022 06:23:55 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 10/27/2022 06:23:06 PM
- Statement of Ownership (sc 13g) • Edgar (US Regulatory) • 10/19/2022 02:56:12 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 09/09/2022 08:29:52 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 09/09/2022 08:24:33 PM
- Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) • Edgar (US Regulatory) • 09/09/2022 08:22:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 09/08/2022 10:04:08 AM
- Proxy Statement (definitive) (def 14a) • Edgar (US Regulatory) • 08/31/2022 08:06:35 PM
- Amended Statement of Beneficial Ownership (sc 13d/a) • Edgar (US Regulatory) • 08/26/2022 08:49:18 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/22/2022 10:01:35 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 08/19/2022 09:10:11 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 08/15/2022 08:29:36 PM
FEATURED Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • Mar 31, 2023 7:07 AM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM